The prestigious 2015 Lupus Insight Prize was awarded to investigator George C. Tsokos, MD, who serves as chief of the Rheumatology Division at Beth Israel Deaconess Medical Center as well as professor of Medicine at Harvard Medical School. Dr. Tsokos was selected by the Alliance for…
The Lupus Research Institute and the S.L.E. Lupus Foundation are two of the over 200 patient organizations that are part of the “I Am (Still) Essential” coalition, which has recently advocated for changes in the Essential Health Benefits for 2016 with the U.S. Department of Health and Human Services (HHS). The organizations believe…
Representatives of Lupus Agencies of New York State, the S.L.E. Lupus Foundation and Lupus Research Institute recently joined together at the New York State Capitol to raise awareness about the disease on Annual Lupus Awareness Day, last Wednesday, May 13th. The state of New York is celebrating May as …
Thousands of children and young people in the United States struggle with lupus. The treatment of the condition requires more aggressive drugs than for adult patients and the adverse effects of the drugs impact biological, psychological, and social development. To study the issue, a team of researchers at the Children’s Hospital…
Researchers at Monash University’s Department of Immunology recently developed a method to prevent lupus by targeting a specific receptor in B cells. B cells are a key type of immune cell responsible for defending the body against infections, producing antibodies and generating memory B cells that remain in the body so that, if encountering…
A team led by researchers at Garvan Institute of Medical Research and St. Vincent’s Clinical School in Australia identified a new trigger for autoimmune diseases. The study was recently published in the journal Immunity and is entitled “FAS Inactivation Releases Unconventional Germinal…
Patients who suffer from systemic lupus erythematosus (SLE) or lupus nephritis (LN) may have seven new therapeutic options by 2022, according to a new report on the global drug market. The forecast published by the company Research and Markets analyzed the lupus treatment market over the past few decades,…
Results from a survey conducted by GfK in 2014 indicated that patients with systemic lupus erythematosus (SLE) have difficulties describing their symptoms to their physicians, leading to a gap in physicians’ understanding of the full impact the illness has on these patients’ lives. The survey was conducted by GfK on…
Inducing ovarian suppression in female patients with childhood-onset systemic lupus erythematosus (SLE) is protective against ovarian failure from treatment with cyclophophamide. A clinical trial from Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine has established a safe dose of triptorelin that effectively achieves and maintains complete…
A study recently published in the journal Arthritis & Rheumatology revealed that proteinuria is an accurate clinical predictor of long-term renal outcome in patients with lupus nephritis. The study was conducted by an international research team and is entitled “Predictors of Long-Term Renal Outcome…